5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
about
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGCancer Treatment and Bone Health.
P2860
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@ast
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@en
type
label
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@ast
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@en
prefLabel
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@ast
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@en
P2093
P2860
P356
P1433
P1476
5-year follow-up of a randomiz ...... xifen: N03CC (Alliance) trial.
@en
P2093
Ann E Kearns
Charles L Loprinzi
Edith A Perez
Heshan Liu
Jacqueline M Lafky
Jeff A Sloan
Nina D Wagner-Johnston
Shaker R Dakhil
Stephanie L Hines
Suneetha Puttabasavaiah
P2860
P304
P356
10.1002/CNCR.29327
P407
P577
2015-04-30T00:00:00Z